Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing allergic reaction among the target population
3.2.1.2 Increasing research and development investments
3.2.1.3 Technological advancements in drug delivery systems
3.2.1.4 Expanding applications beyond allergic reactions
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with the medication
3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Tablets
5.3 Capsules
5.4 Injections
5.5 Syrups
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Intramuscular
Chapter 7 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Histamine-mediated pruritus
7.3 Urticaria
7.4 Atopic contact dermatitis
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Alliance Pharma Plc
10.2 Amneal Pharmaceuticals, Inc.
10.3 Aurobindo Pharma Limited
10.4 Glenmark Pharmaceuticals Ltd.
10.5 MYLAN N.V.
10.6 Novartis AG
10.7 Pfizer Inc.
10.8 Piramal Enterprises Limited
10.9 Sun Pharmaceutical Industries Limited
10.10 Teva Pharmaceutical Industries Limited
